- A +

Gene Therapy Against Blindness

We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.

Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative ophthalmology companies.

Our initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases.


2015 Next events


ISOPT, July 9-12, 2015, Berlin, Germany

GenSigth will present at an oral session : A Recombinant AAV2/2 Carrying the Wild-Type ND4 Gene for the Treatment of LHON: Preliminary Results of a First-In-Man Study and Upcoming Pivotal Efficacy Trials


ESGCT, September 17-20, 2015, Helsinki, Finland

GenSight will participate to this annual meeting that gathers nearly 1,000 participants from 40 countries as scientists, clinicians and industry professionals to share new data, learn from peers, and discover global advances within the Gene and Cell Therapy field. 


Phacilitate Cell&Gene Therapy Europe, September 29-30, Barcelona, Spain

GenSight will participate and will give an oral presentation on Day1 in  Focus session 2 on "Early Clinical Strategy: How to efficiently navigate european ATMP regulations on a national basis"

 July, 6 2015

SIGHT AGAIN : a collaborative R&D project to restore vision to legally blind patients with retinitis pigmentosa at different stages

GenSight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total €18.5 million funding for SIGHT AGAIN as part of the Investment for the Future. This public - private project with an overall budget of € 47 million aims to restore vision to legally blind patients with retinitis pigmentosa at different stages of the disease.

Other news

06 May 2014

GenSight Biologics appoints Jean-Philippe Combal as Chief Operating Officer

Paris, France, May 6th, 2014 – GenSight Biologics, a pioneer of innovative gene therapy based solutions to preserve or restore vision in people with degenerative retinal and inherited ophthalmologic diseases, announces the appointment of Jean-Philippe Combal as Chief Operating Officer (“COO”). Dr Combal will lead the Company’s operational activities and the development of its products.

08 April 2013

GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy

Paris, France, April 8th, 2013 – GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

Read all news

Discover our videos